MdxHealth (TM) : MDxHealth (TM) : Annual and Extraordinary General Shareholders' Meeting

      MdxHealth (TM) : MDxHealth (TM) : Annual and Extraordinary General
                            Shareholders' Meeting



IRVINE, CA, and  LIEGE, BELGIUM, 31  May, 2013 -MDxHealth  SA (NYSE  Euronext: 
MDXH), a leading molecular diagnostic company that develops and commercializes
epigenetic  tests  to   support  cancer   treatment,  held   its  Annual   and 
Extraordinary  General  Meeting  of   shareholders  in  Zaventem  today.   The 
shareholders  approved  all  agenda  items  of  the  Annual  General  Meeting, 
including the financial statements  for the financial  year ended 31  December 
2012.

The quorum requirement for deliberation and voting on the agenda items of  the 
Extraordinary General  Meeting was  not met.  A second  Extraordinary  General 
Meeting will be  held on  Thursday 27  June 2013 at  10:00 AM  at the  Airport 
Meeting Center, Brussels Airport, Box 75,  1930 Zaventem, Belgium, or at  such 
place as will be indicated at that place at that time.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain, lung and colon cancers. The company is based  in 
Irvine, California with a  European headquarters in  Liege, Belgium. For  more 
information visit MDxHealth's website at www.mdxhealth.com.

For more information: Mike Sinclair          Seth Lewis
Dr. Jan Groen, CEO    Halsin Partners        The Trout Group
MDxHealth             UK: +44 20 7318 2955
US: +1 949 812 6979   Cell: +44 7968 022075  US: +1 646 378 2952
BE: +32 4 364 20 70   msinclair@halsin.com  slewis@troutgroup.com 
info@mdxhealth.com 



This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.



NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1706177
 
Press spacebar to pause and continue. Press esc to stop.